INTRODUCTION
============

Hospital-acquired (HA) methicillin-resistant *Staphylococcus aureus* (MRSA) infections are a major cause of illness and death and impose serious economic costs on patients and hospitals. The estimated number of *S. aureus*-related hospitalizations increased by 62% from 294,570 to 477,927, and the estimated number of MRSA-related hospitalizations more than doubled, from 127,036 to 278,203, from 1999 through 2005 in the United States \[[@b1-kjim-2017-098]\]. Published studies on mortality for patients with *S. aureus* bacteremia (SAB) indicated an increased risk of mortality for patients with MRSA compared to those with methicillin-susceptible *S. aureus* (MSSA) bacteremia \[[@b2-kjim-2017-098]\]. Thus bacteremia due to HA-MRSA results in increased direct medical costs and hospital stays, compared with that due to MSSA \[[@b3-kjim-2017-098]\].

Cases of MRSA have been documented among healthy community-dwelling persons without established risk factors for MRSA acquisition, lately defined as community-associated (CA)-MRSA \[[@b4-kjim-2017-098]\]. Community-genotype strains carrying SCC*mec* type IV have now emerged as a significant cause of healthcare-associated (HCA) and hospital associated (HA) infections in the USA and European countries \[[@b5-kjim-2017-098]-[@b9-kjim-2017-098]\]. Despite the epidemiologic changes in hospital MRSA strains with the encroachment of CA-MRSA into healthcare settings \[[@b9-kjim-2017-098],[@b10-kjim-2017-098]\], whether methicillin resistance adversely affects outcomes in patients with community-associated *S. aureus* bacteremia is unclear \[[@b11-kjim-2017-098],[@b12-kjim-2017-098]\]. After the year 2000, newer antimicrobial agents active against MRSA have become available to treat MRSA and are in use as alternatives for treating serious MRSA infections. The efficacy of new antibiotics in terms of reducing mortality in patients infected with *S. aureus*, especially MRSA, has not been verified. Furthermore, progress in high-quality clinical management has been made in the last few years as evidenced by the fact that case fatality can be reduced by hospital infection control systems \[[@b13-kjim-2017-098]\]. These factors, including the emergence of MRSA strains with reduced vancomycin susceptibility, enhanced the controversy regarding the clinical impact of methicillin resistance on outcomes in SAB \[[@b14-kjim-2017-098]\].

Meta-analyses by Cosgrove et al. \[[@b2-kjim-2017-098]\] and Whitby et al. \[[@b15-kjim-2017-098]\] comparing the mortality rate of MRSA and MSSA bacteremia found that methicillin resistance was associated with an increased mortality. In a recent meta-analysis, a significant increase in mortality associated with MRSA bacteremia was evident in the odds ratio (OR) of 1.93 (95% confidence interval \[CI\], 1.54 to 2.42), when 31 articles were combined with data regarding mortality associated with both MSSA and MRSA bacteremia \[[@b2-kjim-2017-098]\]. There were also worse outcomes in studies that involve nosocomial SAB, compared to those involving a significant proportion of CA-SAB \[[@b2-kjim-2017-098]\]. However, in the era of the emergence of CA-MRSA and the advent of newer antimicrobial agents active against MRSA, the impact of methicillin-resistance on mortality and medical costs for patients with SAB needs to be reevaluated. Therefore, we performed a systematic review and meta-analysis to investigate the effect of methicillin-resistance on mortality, length of hospital stay and medical costs of patients with SAB based on reports published after the year 2000.

METHODS
=======

Literature search and selection of eligible studies
---------------------------------------------------

We searched studies of SAB or endocarditis using electronic databases including Ovid-Medline, Embase-Medline, and the Cochrane Library, as well as five local databases providing information on Korean medical research, published from January 1, 2000 to September 15, 2011. We used the search filter recommended by the Scottish Intercollegiate Guidelines Network to efficiently identify cohort studies. We also reviewed the bibliographies of relevant articles to identify additional publications. A full-text search of eight databases in English or Korean were reviewed using the terms "*Staphylococcus aureus*" AND "bacteremia" OR "endocarditis." Two reviewers (D.A.P. and S.M.L.) independently evaluated titles, abstracts and citations to assess relevance for full review. We applied no language restriction in the electronic database search, which was limited to studies involving humans.

The inclusion criteria were as follows: studies (1) targeting SAB or *S. aureus* endocarditis (SAE); (2) comparison of outcomes of MRSA and MSSA; (3) evaluating any type of mortality, the length of hospital stay (LOS) or medical costs; and (4) involving adults 18 years older. The exclusion criteria were as follows: (1) not original research; (2) animal or pre-clinical studies; (3) not cohort studies; (4) only an abstract; (5) studies not published in Korean or English; and (6) duplicate reports. Therefore, all cohort studies in adults with SAB or endocarditis were included if they compared outcomes of MRSA to those of MSSA. Outcomes of methicillin-resistance were analyzed in terms of all-cause mortality, in-hospital mortality, SAB-related mortality, and 30-day mortality. The LOS and medical costs were also compared between the MRSA and MSSA groups. Studies involving children or neonates and those of a case-control design were excluded. We also excluded studies involving the same population during an overlapping 1-year study period.

Since this study had evaluated the published data of applicable studies, it was not required to obtain approval by the Institutional Review Board. Obtaining written informed consent was not applicable in the performance of a meta-analysis where no foreseeable harm is expected to result from the study.

Data extraction
---------------

Using a standardized form developed in advance, two independent reviewers extracted the following pre-specified data: first author, publication year, country, study period, study setting, study design, total number of study participants, the number and proportion of individuals in the MRSA and MSSA groups, age, proportion of males, cases with nosocomial- and community-acquired bacteremia, SAE, and results of predetermined outcomes during the follow-up period. We also collected the adjusted estimates of mortality in SAB and endocarditis and confounding variables considered in the statistical models of each study. Agreement was obtained after discussion between the two reviewers. We did not assess the methodological quality of included studies because most did not differ in design or in the methods used for recruiting participants.

Data synthesis and analysis
---------------------------

We employed a random-effects model using the method described by DerSimonian and Laird \[[@b16-kjim-2017-098]\] to synthesize data from included studies. For the outcome data on mortality, we calculated the OR and 95% CI as summary statistics. For continuous outcomes, such as the length of hospital stay and medical costs, weighted mean differences (WMDs) and 95% CIs were calculated.

We assessed statistical heterogeneity using the Cochrane Q-test (*p* \< 0.10) and *I^2^* statistic, with *I^2^* \> 50% indicating at least moderate heterogeneity \[[@b17-kjim-2017-098]\]. To assess the potential explanations for heterogeneity, we performed subgroup analyses using pre-specified criteria including disease characteristics (bacteremia including mixed populations and endocarditis) and the type of infection (community-acquired infections and ≥ 70% vs. \< 70% nosocomial infection). We also performed sensitivity analyses using summary estimates in studies adjusted for confounding variables. First, we used a funnel plot asymmetry approach to assess publication bias qualitatively, and then we confirmed the symmetry of the funnel plot using Begg and Mazumdar's rank correlation test ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}) \[[@b18-kjim-2017-098],[@b19-kjim-2017-098]\]. If publication bias was suspected, we performed the Trim and Fill method to obtain symmetry in the funnel plot and to determine the effect of hypothetical studies on the pooled estimate \[[@b20-kjim-2017-098]\]. Statistical analysis was performed using Review Manager version 5.0 (RevMan, The Cochrane Collaboration, Oxford, UK) and Stata software version 10.0 (SE, Stata Corp., College Station, TX, USA). A *p* value of 0.05 was regarded as statistically significant.

RESULTS
=======

Study populations
-----------------

A total of 2,841 studies were searched from January 2000 through September 2011. Of 2,075 studies from which duplicated reports were eliminated, 92 (eight studies in Korea and 84 in other countries) were selected after the first and second literature review. A flow diagram of identification of eligible studies is shown in [Fig. 1](#f1-kjim-2017-098){ref-type="fig"}. Of these, 62 cohort studies were selected as eligible that reported any outcome regarding mortality, LOS and medical costs after review of the full-text of articles ([Table 1](#t1-kjim-2017-098){ref-type="table"}) \[[@b21-kjim-2017-098]-[@b82-kjim-2017-098]\]. Pooled data for 17,563 patients (6,390 MRSA and 11,173 MSSA) were included in the analysis. All were cohort studies, comprising 41 retrospective, 20 prospective and one both retro- and prospective study. The characteristics of the selected studies are shown in [Table 1](#t1-kjim-2017-098){ref-type="table"} according to year of publication.

Mortality in patients with methicillin-resistant and methicillin-susceptible SAB and endocarditis
-------------------------------------------------------------------------------------------------

Of the 62 studies, 60 reported all-cause mortality including in-hospital mortality, 14- and 30-day mortality and SAB-related mortality. The clinical characteristics of all patients with MRSA and MSSA in the 62 studies are summarized in [Table 1](#t1-kjim-2017-098){ref-type="table"}. A significant increase in all-cause mortality associated with MRSA was evident with a pooled OR of 1.95 (95% CI, 1.73 to 2.21; *I^2^* = 44%) compared to that of MSSA ([Fig. 2](#f2-kjim-2017-098){ref-type="fig"}) \[[@b21-kjim-2017-098]-[@b82-kjim-2017-098]\]. The pooled OR for 40 studies that reported in-hospital mortality was 1.90 (95% CI, 1.57 to 2.28; *I^2^* = 51%). In 13 studies that compared 30-day mortality rates in SAB, MRSA increased the odds of death 1.89-fold compared to MSSA (95% CI, 1.58 to 2.26; *I^2^* = 40%). In the 16 studies that documented SAB or infection-related mortality, generic inverse variance methods were used. The pooled OR was 2.04 (95% CI, 1 63 to 2.55; *I^2^* = 40%).

Of the 62 selected studies, 13 reported the outcomes of SAE, among which 10 involved a population with SAE \[[@b30-kjim-2017-098],[@b35-kjim-2017-098],[@b40-kjim-2017-098],[@b47-kjim-2017-098],[@b55-kjim-2017-098],[@b61-kjim-2017-098],[@b64-kjim-2017-098],[@b65-kjim-2017-098],[@b68-kjim-2017-098],[@b71-kjim-2017-098]\], and the remaining three reported outcomes of SAE as part of SAB episodes \[[@b26-kjim-2017-098],[@b31-kjim-2017-098],[@b82-kjim-2017-098]\]. Methicillin-resistance increased the risk of mortality by 2.65-fold in those patients (95% CI, 1.46 to 4.80; *I^2^* = 50%). There was no significant heterogeneity among the results of these studies. Further analysis primarily involving the SAE population showed a pooled OR of 3.32 (95% CI, 1.68 to 6.59).

Mortality in patients with methicillin-resistant and methicillin-susceptible SAB and endocarditis in the Korean population
--------------------------------------------------------------------------------------------------------------------------

In a meta-analysis of eight studies which reported all-cause mortality in SAB and endocarditis in the Korean population, methicillin-resistance was associated with increases in mortality with a pooled OR of 3.14 (95% CI, 1.48 to 6.67) ([Fig. 3](#f3-kjim-2017-098){ref-type="fig"}) \[[@b24-kjim-2017-098],[@b26-kjim-2017-098],[@b35-kjim-2017-098],[@b51-kjim-2017-098],[@b52-kjim-2017-098],[@b64-kjim-2017-098],[@b69-kjim-2017-098],[@b71-kjim-2017-098]\]. There was significant heterogeneity among the results of these studies (*I^2^* = 76%). Of eight studies, three studies analyzed the outcomes of SAE in Korean populations \[[@b35-kjim-2017-098],[@b64-kjim-2017-098],[@b71-kjim-2017-098]\]; in these, the mortality risk of MRSA increased 14.19-fold compared to that of MSSA (95% CI, 3.84 to 52.41).

Community- and hospital-acquired SAB
------------------------------------

Twenty-two studies reported outcomes of CA-SAB; of these, only three studies compared mortality rates between CA-MRSA and CA-MSSA. MRSA increased the odds 3.23-fold, compared to MSSA (95% CI, 1.25 to 8.34) when the three studies were combined ([Fig. 4](#f4-kjim-2017-098){ref-type="fig"}) \[[@b31-kjim-2017-098],[@b39-kjim-2017-098],[@b74-kjim-2017-098]\]. Forty-one studies reported the outcomes in patients of nosocomial SAB. In the 13 selected studies in which ≥ 70% of the cases of SAB were hospital-acquired, the pooled OR was 1.70 (95% CI, 1.29 to 2.25). In contrast, in 28 studies in which less than 70% were nosocomial, the OR was 1.95 (95% CI, 1.66 to 2.29).

LOS, ICU stay, and medical costs
--------------------------------

LOS was divided into two categories for analysis---the total LOS and the length of stay after the onset of bacteremia. Eight studies reported total LOS ([Table 2](#t2-kjim-2017-098){ref-type="table"}) \[[@b29-kjim-2017-098],[@b37-kjim-2017-098],[@b45-kjim-2017-098],[@b63-kjim-2017-098],[@b66-kjim-2017-098],[@b67-kjim-2017-098],[@b75-kjim-2017-098],[@b82-kjim-2017-098]\]. Of them, four studies were combined for the meta-analysis of total LOS \[[@b37-kjim-2017-098],[@b63-kjim-2017-098],[@b67-kjim-2017-098],[@b75-kjim-2017-098]\]. The average total LOS in the MRSA group was 10.03 days longer than that in the MSSA group; this difference was significant (WMD, 10.03; 95% CI, 3.36 to 16.70; *I^2^* = 83%). The result of a sensitivity analysis, excluding the heterogeneous studies, indicated that patients with MRSA bacteremia stayed 6.72 days longer (WMD, 6.72; 95% CI, 3.38 to 10.0) than those with MSSA bacteremia without heterogeneity (*I^2^* = 31%). Among six studies that reported length of stay after the onset of bacteremia, data from two studies \[[@b62-kjim-2017-098],[@b63-kjim-2017-098]\] were included in the analysis and showed that the average stay was 5.02 days longer in the MRSA group than the MSSA group (WMD, 5.02; 95% CI, 2.66 to 7.38), with homogeneity (*I^2^* = 0%). Four studies described the length of intensive care unit (ICU) stay. Patients with MRSA bacteremia stayed in the ICU 6.46 days longer (WMD, 6.46; 95% CI, 0.87 to 12.04), with heterogeneity among combined studies (*I^2^* = 86%) than those with MSSA. Of six studies that reported medical costs ([Table 3](#t3-kjim-2017-098){ref-type="table"}) \[[@b33-kjim-2017-098],[@b37-kjim-2017-098],[@b46-kjim-2017-098],[@b62-kjim-2017-098],[@b63-kjim-2017-098],[@b76-kjim-2017-098]\], two were included in the analysis, and the estimated medical costs were \$9,954.58 (WMD, 9,954.58; 95% CI, 8,951.99 to 10,957.17) with a statistically significant difference between groups and homogeneity between the two studies (*I^2^* = 0%) \[[@b62-kjim-2017-098],[@b63-kjim-2017-098]\].

Publication bias
----------------

We generated contour-enhanced funnel plots to evaluate the presence of potential publication bias for the meta-analyses performed in our review ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). No evidence of publication bias was noted in the funnel plots and the adjusted rank correlation tests in the meta-analyses for all-cause mortality (*p* = 0.10), in-hospital mortality (*p* = 0.056), 30-day mortality (*p* = 0.714), or SAB-related mortality (*p* = 0.557).

DISCUSSION
==========

This systematic review of 62 relevant reports published since 2000 that evaluated the outcomes of SAB and endocarditis in adults, suggested that methicillin-resistant isolates is associated with increased mortality, hospital stay and medical costs, compared with susceptible isolates. A significant increase in all-cause mortality associated with MRSA, compared to that with MSSA compromised of 17,565 patients from 62 combined studies was evident with a pooled OR of 1.95. This is consistent with the report in 2003 by Cosgrove et al. \[[@b2-kjim-2017-098]\] which had combined 31 studies with a total of 3,962 patients of an OR of mortality associated with MRSA of 1.93, compared with MSSA. In 60 studies that reported mortality outcomes, the relative risk (RR) was estimated to be 1.59 based on the mean mortality rate of 33.1% (2,101/6,338) in the MRSA group and 18.2% (2,014/11,075) in the MSSA group. In studies of in-hospital mortality, the RR was estimated at 1.54. This is also similar to the RR of 1.42 reported by Cosgrove et al. \[[@b2-kjim-2017-098]\]. In the analysis involving SAB-related mortality, the pooled OR was 2.04 (95% CI, 1.63 to 2.55; *I^2^* = 40%). This was compatible with the OR of 2.2 (95% CI, 1.2 to 3.8) reported by Cosgrove et al. \[[@b2-kjim-2017-098]\]. In this analysis reevaluating the impact of methicillin-resistance on mortality in the era of the changing epidemiology and treatment of MRSA infections, a similar trend for a strong association between methicillin-resistance and a significantly increased mortality risk was identified through a review of the literature. Through a systematic review using a database published since the year 2000, two studies reported length of stay after the onset of bacteremia; patients in the MRSA group stayed 5.02 days longer than those in the MSSA group (95% CI, 2.66 to 7.38).

We also intended to evaluate the risk of mortality in endocarditis by comparing the groups with MRSA and MSSA. Interestingly, methicillin resistance increased the risk of mortality in SAE by 2.65 (95% CI, 1.46 to 4.80). Further analysis, involving primarily the SAE population, showed a pooled OR of 3.32 (95% CI, 1.68 to 6.59), which is higher than that reported by Cosgrove et al. \[[@b2-kjim-2017-098]\] 1.79 (95% CI, 0.84 to 3.81). This is different than our expectation that mortality would be lower among patients with MRSA endocarditis as a consequence of better management with new antibiotics. Although glycopeptides were the only treatment option for MRSA infections before 2000, new treatment agents, including daptomycin and linezolid, for MRSA have been introduced since that time. Hence, the outcomes in the MRSA group were expected to be better than those in the past, especially in SAE, which is a severe form of SAB. The increased risk of mortality in the SAE group is attributable in part to the delay between data collection and publication. More than half of the study population was collected before 2000. Besides, only fifteen studies specified the treatment regimens for SAB; the mainstay of therapy for these was limited to glycopeptides. There was no study evaluating the clinical outcomes of SAB according to the treatment regimens between glycopeptides and the new anti-MRSA agents among the 62 relevant studies. Thus, the estimated risk in our analysis does not fully reflect changes in treatment of MRSA infections using new antibiotics as alternatives to glycopeptides. Further studies are required to evaluate the risk of methicillin-resistance for mortality in the SAE population under treatments with antibiotics other than glycopeptides.

Traditionally, bacteremia and endocarditis are classified as either CA or HA (nosocomial). CA-MRSA infections have emerged in the past few years as an important medical problem, especially in children without traditional risk factors for healthcare-associated MRSA. To evaluate the risk for emergence of methicillin-resistance in the community, we examined the outcomes of 22 studies reporting outcomes for CA-SAB as part of SAB; of these, three studies reported outcomes by comparing CA-MRSA and CA-MSSA. Interestingly, methicillin-resistance increased the risk of death by 3.23 (95% CI, 1.25 to 8.34). Furthermore, in nosocomial SAB, methicillin-resistance had a relatively low risk of morality in adults with ≥ 70% HA-SAB, compared to those with \< 70% HASAB. These findings are opposed to previous reports in adults, which have described non-severe outcomes in CA-SAB compared to those in HA-SAB with a few notable exceptions. Given the different distribution pattern of CA- and HA-SAB, empiric antimicrobial therapy for CA-SAB could be less appropriate than for patients with HA-SAB. Since clinical practice guidelines for the treatment of MRSA often do not recommend coverage for CA-MRSA, the association between the presence of CA-MRSA and mortality in SAB suggests that patients with CA-MRSA were more likely to have received antibiotics not effective against methicillin-resistant strains \[[@b83-kjim-2017-098]\]. Heterogeneity among study results, however, was detected in subgroup analyses; thus, further studies are required to determine the impact of methicillin-resistance on outcomes in adults with CA-SAB.

This study had several limitations. First, we included all adult subjects irrespective of disease patterns and severity of illness in this meta-analysis; this wide distribution of subject characteristics may result in heterogeneity between the combined studies. In this study, however, the heterogeneity test results were considerably lower than those in the general meta-analysis by Cosgrove et al. \[[@b2-kjim-2017-098]\]. When we assessed the statistical heterogeneity with *I^2^* \> 50% as the indication of at least moderate heterogeneity, between-study statistical heterogeneity was not found in this meta-analysis (*I^2^* statistic, 44%). Twenty-two studies were selected as high-quality in the assessment of bias risk of 62 relevant papers; with these, the sensitivity analysis showed a pooled OR of 2.12 (95% CI, 1.76 to 2.55), a significantly increased risk of mortality of methicillin- resistance in SAB. Heterogeneity in the combined studies was not identified (*I^2^* = 46%). Thus heterogeneity did not have a major impact on the results. Therefore, a wide distribution of subject characteristics between studies in this meta-analysis is not considered to have had a huge impact on the results. Second, this analysis included data in part collected before the year 2000. Given that our data were collected around 2000, the mainstay of therapy for MRSA in this analysis was confined to glycopeptides; this may not fully reflect current medical treatment, in which newer antimicrobial agents active against MRSA have become available. Further study of the effect of new antimicrobial agents on mortality of patients with SAB is required.

Despite these limitations, the present systematic review of studies published since 20 suggests that methicillin-resistance is associated with increased mortality and hospital stay compared with susceptible isolates in SAB and endocarditis. In the SAE and CA-SAB infection subgroups, methicillin-resistance was associated with increased mortality.

KEY MESSAGE
===========

1\. Methicillin-resistance is still associated with increased mortality and hospital stay, compared with susceptible isolates in *Staphylococcus aureus* bacteremia.

2\. In comparison of outcome between community-acquired methicillin-resistant and methicillin-susceptible *S. aureus* bacteremia, methicillin-resistance increased the risk for mortality.
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###### 

Contour-enhanced funnel plot and Begg & Mazumdar's rank correlation test for exploring publication bias for all-cause mortality (A), in-hospital mortality (B), 30-day mortality (C), and *Staphylococcus aureus* bacteremia-related mortality (D).

![Flow diagram detailing reviewed articles and exclusion. DB, database.](kjim-2017-098f1){#f1-kjim-2017-098}

![Forest plot summary of the results of 60 studies which reported all-cause mortality. MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-susceptible *S. aureus*; CI, confidence interval.](kjim-2017-098f2){#f2-kjim-2017-098}

![Forest plot summary of results of eight which reported all-cause mortality in *Staphylococcus aureus* bacteremia and endocarditis in the Korean population. MRSA, methicillin-resistant *S. aureus*; MSSA, methicillin-susceptible *S. aureus*; CI, confidence interval.](kjim-2017-098f3){#f3-kjim-2017-098}

![Forest plot summary of results of three studies which reported mortality rates between community-associated (CA)-methicillin-resistant *Staphylococcus aureus* (MRSA) and CA-methicillin-susceptible *S. aureus* (MSSA). CI, confidence interval.](kjim-2017-098f4){#f4-kjim-2017-098}

###### 

Characteristics of the studies of *Staphylococcus aureus* bacteremia or endocarditis included in the systematic review

  No.              Author                                    Year   Study period             Country        Total no. of cases   Proportion of HAMRSA/CAMRSA/MSSA^a,b,c^                         Population        IE (% of cases)   Types of outcomes                                                                Mortality rate, %   Crude OR (95% CI)   
  ---------------- ----------------------------------------- ------ ------------------------ -------------- -------------------- --------------------------------------------------------------- ----------------- ----------------- -------------------------------------------------------------------------------- ------------------- ------------------- ------------------------
  1                Holmes \[[@b21-kjim-2017-098]\]           2011   2007.1--2008.11          Australia      532                  22.2/15.8/62.0^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^   SAB                                 30-Day mortality                                                                 22.1                14.2                1.72 (1.09--2.71)
  New Zealand                                                                                                                                                                                                                                                                                                                                                 
  2                Kao \[[@b22-kjim-2017-098]\]              2011   2004.1--2004.12          Taiwan         137                  42.3/5.8/51.8^[a](#tfn1-kjim-2017-098){ref-type="table-fn"}^    SAB                                 Hospital mortality                                                               43.9                21.1                2.93 (1.38--6.19)
  3                Lubart \[[@b23-kjim-2017-098]\]           2011   2004.1--2005.12          Israel         68                   66.2/33.8^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 14-Day mortality                                                                 40.0                13.0                4.44 (1.15--17.18)
  4                Park \[[@b24-kjim-2017-098]\]             2011   2003.1--2008.12          Korea          266                  46.6/7.9/45.5^[a](#tfn1-kjim-2017-098){ref-type="table-fn"}^    SAB                                 30-Day mortality                                                                 21.4                28.9                0.67 (0.38--1.17)
  5                Big \[[@b25-kjim-2017-098]\]              2010   2004.1--2008.7           USA            76                   60.5/39.5^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 Hospital mortality                                                               34.8                20.0                2.13 (0.72--6.29)
  6                Kang \[[@b26-kjim-2017-098]\]             2010   2004.9--2006.8           Korea          709                  46.4/53.6^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB/SAE           31 (4.4)          30-Day mortality                                                                 33.1                17.1                2.40 (1.69--3.41)
  7                Khan \[[@b27-kjim-2017-098]\]             2010   2007.7--2008.6           Qatar          53                   13.2/86.8^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 Hospital mortality                                                               28.6                28.3                1.02 (0.17--5.91)
  8                Kim \[[@b28-kjim-2017-098]\]              2010   2006.7--2008.12          Canada         684                  27.9/72.1^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 30-Day mortality                                                                 25.1                15.4                1.84 (1.22--2.77)
  9                Ponce-de-Le-on \[[@b29-kjim-2017-098]\]   2010   2003.1--2007.12          Mexico         172                  45.9/0/54.1^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^      SAB                                 30-Day mortality, hos- pital mortality, 7-day mortality, LOS                     21.5                21.5                1.0 (0.48--2.08)
  10               Takayama \[[@b30-kjim-2017-098]\]         2010   1990.1--2006.12          Japan          33                   30.3/0/69.7^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^      SAE               33 (100)          Hospital mortality                                                               70.0                34.8                4.38 (0.88--21.71)
  11               Wehrhahn \[[@b31-kjim-2017-098]\]         2010   2-Year period            Australia      81                   0/22.2/77.8^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^      SAB/SAE           15 (18.5)         30-Day mortality                                                                 22.2                11.1                2.29 (0.59--8.91)
  12               Ammerlaan \[[@b32-kjim-2017-098]\]        2009   2007.1--2007.12          Europe         334                  23.1/76.9^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 30-Day mortality                                                                 26.0                23.3                1.15 (0.64--2.07)
  13               Ben-David \[[@b33-kjim-2017-098]\]        2009   2000.1--2003.8           Israel         182                  52.2/0/47.8^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^      SAB                                 Hospital mortality, LOS, total medical cost                                      25.3                18.4                1.5 (0.74--3.06)
  14               Khatib \[[@b34-kjim-2017-098]\]           2009   2002.1--2003.6           USA            78                   78.2/21.8^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 Hospital mortality                                                               34.4                5.9                 8.4 (1.04--67.79)
  15               Kim \[[@b35-kjim-2017-098]\]              2009   1995.1.--2006.12         Korea          73                   16.4/26.0/57.5^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^   SAE               73 (100)          Hospital mortality,                                                              35.5                2.4                 22.55 (2.72--187.07)
  16               Rieg \[[@b36-kjim-2017-098]\]             2009   2002--2007               Germany        521                  12.9/0/87.1^[a](#tfn1-kjim-2017-098){ref-type="table-fn"}^      SAB                                 Hospital mortality                                                               41.8                18.7                3.12 (1.82--5.35)
  17               Rubio-Terres \[[@b37-kjim-2017-098]\]     2009   2005.1--2005.12          Spain          366                  26.8/6.3/66.9^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^    SAB                                 Hospital mortality, LOS (in wards), ICU stay, cost per episode bacteremia        39.7                25.3                1.94 (1.22--3.09)
  18               Turnidge \[[@b38-kjim-2017-098]\]         2009   2007.6--2008.5           Australia      1865                 24.1/75.9^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 30-Day mortality                                                                 30.0                17.7                2.0 (1.57--2.55)
  New Zealand                                                                                                                                                                                                                                                                                                                                                 
  19               Allard \[[@b39-kjim-2017-098]\]           2008   1991--2005               Canada         815                  8.3/0.1/91.5^[a](#tfn1-kjim-2017-098){ref-type="table-fn"}^     SAB                                 30-Day mortality                                                                 33.3                23.1                1.67 (0.98--2.83)
  20               Baroudi \[[@b40-kjim-2017-098]\]          2008   1990.1--2006.1           USA            27                   55.6/44.4^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAE               27 (100)          Hospital mortality                                                               40.0                50.0                0.67 (0.14--3.09)
  21               Libert \[[@b41-kjim-2017-098]\]           2008   2002.1--2004.12          Belgium        140                  31.4/12.9/55.7^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^   SAB                                 Hospital mortality                                                               54.8                35.9                1.90 (0.97--3.76)
  22               Malani \[[@b42-kjim-2017-098]\]           2008   2004--2005               USA            68                   52.9/47.1^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 Hospital mortality                                                               25.0                12.5                3.88 (1.29--11.68)
  23               Bader \[[@b43-kjim-2017-098]\]            2007   2003.1--2004.12          USA            135                  23.0/31.8/45.2^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^   SAB                                 Hospital mortality                                                               33.8                18.0                2.32 (1.03--5.22)
  24               Cagatay \[[@b44-kjim-2017-098]\]          2007   2001.10--2002.12         Turkey         57                   80.7/19.3^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 SAB-related mortality (30-day)                                                   54.3                63.6                0.68 (0.17--2.65)
  25               Das \[[@b45-kjim-2017-098]\]              2007   2001--11--2002--12       UK             140                  49.3/10.7/40.0^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^   SAB                                 SAB-related mortality (within 10-day), LOS                                       33.3                16.1                2.61 (1.12--6.08)
  26               Greiner \[[@b46-kjim-2017-098]\]          2007   1999.12--2005.5          Germany        109                  18.3/7.4/74.3^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^    SAB                                 Total hospital cost                                                              NR                  NR                  NR
  27               Hsu \[[@b47-kjim-2017-098]\]              2007   1995--2005               Taiwan         123                  39.0/61.0^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAE               123 (100)         Hospital mortality                                                               41.7                16.0                3.75 (1.61--8.71)
  28               Wang \[[@b48-kjim-2017-098]\]             2007   1990--2004               Taiwan         1148                 74.1/25.9^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 30-Day mortality                                                                 49.8                27.6                2.60 (1.95--3.47)
  29               Depuydt \[[@b49-kjim-2017-098]\]          2006   1992--2002               Belgium        32                   59.4/40.6^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        Bacteremic SAP                      Hospital mortality                                                               72.2                NR                  NR
  30               Guilarde \[[@b50-kjim-2017-098]\]         2006   2000.1--2001.12          Brazil         111                  55.0/45.0^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 SAB-related mortality                                                            47.5                20.0                3.63 (1.54--8.53)
  31               Heo \[[@b51-kjim-2017-098]\]              2006   2000.1--2005.8           Korea          231                  0/27.3/72.7^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^      SAB                                 Hospital mortality                                                               30.2                19.6                1.77 (0.91--3.41)
  32               Kim \[[@b52-kjim-2017-098]\]              2006   1999.1--2003.5           Korea          96                   64.6/3.1/32.3^[a](#tfn1-kjim-2017-098){ref-type="table-fn"}^    SAB                                 Hospital mortality                                                               26.2                0.0                 22.73 (1.32--391.68)
  33               Lesse \[[@b53-kjim-2017-098]\]            2006   1997.1--2003.12          USA            38                   63.2/36.8^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 Hospital mortality                                                               33.3                21.4                1.83 (0.4--8.49)
  34               Marra \[[@b54-kjim-2017-098]\]            2006   2003.12.15--2004.12.31   USA            91                   46.2/53.8^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 Hospital mortality                                                               26.2                4.1                 8.69 (1.80--41.88)
  35               Nori \[[@b55-kjim-2017-098]\]             2006   1999.1--2004.2           USA            22                   50.0/50.0^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAE               22 (100)          Hospital mortality                                                               54.5                45.5                1.44 (0.27--7.71)
  36               Perovic \[[@b56-kjim-2017-098]\]          2006   1999.11--2002.10         South Africa   449                  18.7/4.7/76.6^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^    SAB                                 SAB-related mortality (14-day)                                                   33.3                20.1                1.99 (1.23--3.23)
  37               Shorr \[[@b57-kjim-2017-098]\]            2006   2002--2003               USA            1540                 21.2/6.2/72.6^[a](#tfn1-kjim-2017-098){ref-type="table-fn"}^    SAB                                 Hospital mortality                                                               23.5                16.4                1.57 (1.19--2.06)
  38               Wyllie \[[@b58-kjim-2017-098]\]           2006   1997.4--2004.3           UK             441                  51.5/0/48.5^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^      SAB                                 30-Day mortality                                                                 33.5                27.1                1.35 (0.90--2.04)
  39               Cassettari \[[@b59-kjim-2017-098]\]       2005   1999.5--1999.8           Brazil         163                  58.9/0/41.1^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^      SAB                                 Hospital mortality, SAB-related mortality (15-day)                               44.8                29.9                1.91 (0.99--3.69)
  40               DeRyke \[[@b60-kjim-2017-098]\]           2005   1999.1--2004.4           USA            60                   70.0/0/30.0^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^      Bacteremic SAP                      Hospital mortality, SAB-related mortality, infection-related LOS                 54.8                55.6                0.97 (0.32--2.94)
  41               Fowler \[[@b61-kjim-2017-098]\]           2005   2000.6--2003.12          USA            424                  26.7/6.7/66.7^[a](#tfn1-kjim-2017-098){ref-type="table-fn"}^    SAE               424 (100)         Hospital mortality                                                               29.8                23.3                1.39 (0.89--2.20)
  Multicontinent                                                                                                                                                                                                                                                                                                                                              
  42               Lodise \[[@b62-kjim-2017-098]\]           2005   1999.1--2001.1           USA            353                  39.9/8.2/51.8^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^    SAB                                 SAB-related mortality, 30-day mortality, SAB-related LOS and hospital cost       30.6                15.3                2.44 (1.45--4.10)
  43               Reed \[[@b63-kjim-2017-098]\]             2005   1996.7.--2001.8          USA            143                  37.8/62.2                                                       SAB                                 Hospital-mortality, LOS, ICU stay, total hospital cost                           14.8                9.0                 1.76 (0.62--5.01)
  44               Yoon \[[@b64-kjim-2017-098]\]             2005   1986.3--2004.3           Korea          32                   18.8/12.5/68.8^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^   SAE               32 (100)          Hospital mortality                                                               50.0                9.1                 10.0 (1.48--67.55)
  45               Chang \[[@b65-kjim-2017-098]\]            2004   1988.1--2002.12          Taiwan         12                   66.7/33.3^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAE               12 (100)          Hospital mortality                                                               100                 0                   153.0 (2.58--9,077.05)
  46               Cordova \[[@b66-kjim-2017-098]\]          2004   1997.7--1999.6           Australia      501                  7.8/3.2/89.0^[a](#tfn1-kjim-2017-098){ref-type="table-fn"}^     SAB                                 Hospital mortality (within 16-day), 7-day mortality, LOS                         27.3                16.8                1.86 (0.98--3.53)
  47               Osmon \[[@b67-kjim-2017-098]\]            2004   2001.12--2002.9          USA            265                  36.2/19.6/44.2^[a](#tfn1-kjim-2017-098){ref-type="table-fn"}^   SAB                                 Hospital mortality, LOS, ICU stay                                                13.5                16.2                0.81 (0.41--1.59)
  48               Chang \[[@b68-kjim-2017-098]\]            2003   1994.8--1996.3           USA            64                   15.6/15.6/68.8^[a](#tfn1-kjim-2017-098){ref-type="table-fn"}^   SAE               64 (100)          30-Day mortality, 14-Day mortality                                               50.0                22.7                3.40 (1.10--10.47)
  49               Kim \[[@b69-kjim-2017-098]\]              2003   1998.1--2002.3           Korea          29                   48.3/51.7^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 SAB-related mortality                                                            57.1                20.0                5.33 (1.02--27.76)
  50               Melzer \[[@b70-kjim-2017-098]\]           2003   1995.1--2000.12          UK             815                  46.9/0/53.1^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^      SAB                                 SAB-related mortality, overall mortality                                         29.6                13.6                2.66 (1.87--3.79)
  51               Na \[[@b71-kjim-2017-098]\]               2003   1990.1--2000.5           Korea          10                   20.0/80.0^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAE               10 (100)          Hospital mortality                                                               100                 25                  13.00 (0.45--377.47)
  52               Blot \[[@b72-kjim-2017-098]\]             2002   1992.1.--1998.12         Belgium        85                   55.3/0/44.7^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^      SAB                                 Hospital mortality, 15-day mortality, 30-day mortality, ICU stay                 53.2                18.4                5.03 (1.85--13.69)
  53               Campillo \[[@b73-kjim-2017-098]\]         2002   1996.1--2001.3           France         83                   90.4/0/9.6^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^       SAB/peritonitis                     Hospital mortality                                                               60.0                75.0                0.5 (0.09--2.64)
  54               Talon \[[@b74-kjim-2017-098]\]            2002   1997.1--1998.12          France         99                   11.1/19.2/69.7^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^   SAB               51.7              SAB-related mortality (14-day)                                                   43.3                20.3                3.00 (1.18--7.62)
  55               Tumbarello \[[@b75-kjim-2017-098]\]       2002   1991.1--2000.12          Italy          129                  24.8/7.0/68.2^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^    SAB                                 Hospital mortality, LOS                                                          34.1                11.4                4.04 (1.61--10.17)
  56               Cosgrove \[[@b76-kjim-2017-098]\]         2001   1997.7--2000.6           USA            348                  27.6/72.4^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 Hospital mortality, SAB-related mortality, SAB-related LOS and hospital charge   22.9                19.8                1.20 (0.68--2.12)
  57               Morin \[[@b77-kjim-2017-098]\]            2001   1998.1--1998.12          USA            192                  9.9/5.2/84.9^[a](#tfn1-kjim-2017-098){ref-type="table-fn"}^     SAB                                 Hospital mortality                                                               13.8                10.4                1.37 (0.43--4.42)
  58               Wisplinghoff \[[@b78-kjim-2017-098]\]     2001   1995.12--1997.5          USA            82                   48.8/0/51.2^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^      SAB                                 Hospital mortality                                                               25.0                23.8                1.07 (0.39--2.92)
  59               Ibrahim \[[@b79-kjim-2017-098]\]          2000   1997.6--1999.7           USA            94                   48.9/51.1^[c](#tfn3-kjim-2017-098){ref-type="table-fn"}^        SAB                                 Hospital mortality                                                               37.0                25.0                1.76 (0.73--4.27)
  60               Roghmann \[[@b80-kjim-2017-098]\]         2000   1995.10--1998.1          USA            125                  22.7/7.0/70.3^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^    SAB                                 30-Day mortality                                                                 32.4                23.9                1.53 (0.66--3.57)
  61               Selvey \[[@b81-kjim-2017-098]\]           2000   1992--1997               Australia      504                  37.3/0/62.7^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^      SAB                                 Hospital mortality, SAB-related mortality                                        18.6                13.0                1.53 (0.94--2.51)
  62               Soriano \[[@b82-kjim-2017-098]\]          2000   1991.1--1998.12          Spain          908                  19.9/4.8/75.2^[b](#tfn2-kjim-2017-098){ref-type="table-fn"}^    SAB/SAE           31 (3.4)          SAB-related mortality (30-day), LOS                                              21.8                8.9                 2.84 (1.88--4.28)

HA, hospital-acquired; MRSA, methicillin-resistant *S. aurues*; CA, community-acquired; MSSA, methicillin-susceptible *S. aureus*; IE, infective endocarditis; OR, odds ratio; CI, confidence interval; SAB, *S. aureus* bacteremia; SAE, *S. aureus*-associated infective endocarditis; LOS, length of hospital stay; ICU, intensive care unit; SAP, *S. aureus*-associated pneumonia.

Represents the proportion of cases which were epidemiologically defined according to CA- and HA-MRSA.

Represents the proportion of cases which were classified into community-onset and hospital-onset MRSA without definition of CA-MRSA.

Indicates the proportion of cases with MRSA, when onset of bacteremia was not defined according to the epidemiologic definition.

###### 

Length of hospital stay

  No.   Author                                   Year   Populations   LOS, day                                                            *p* value                                                           
  ----- ---------------------------------------- ------ ------------- ------------------------------------------------------------------- ------------------------------------------------------------------- ------------
  1     Ponce-de-Leon \[[@b29-kjim-2017-098]\]   2010   SAB           31 (1--585)^[a](#tfn4-kjim-2017-098){ref-type="table-fn"}^          21 (0--140)^[a](#tfn4-kjim-2017-098){ref-type="table-fn"}^          0.003
  2     Rubio-Terres \[[@b37-kjim-2017-098]\]    2009   SAB           24.8 (19.9--29.9)^[b](#tfn5-kjim-2017-098){ref-type="table-fn"}^    22.66 (18.8--26.5)^[b](#tfn5-kjim-2017-098){ref-type="table-fn"}^   NR
  3     Das \[[@b45-kjim-2017-098]\]             2007   SAB           14^[c](#tfn6-kjim-2017-098){ref-type="table-fn"}^                   8^[c](#tfn6-kjim-2017-098){ref-type="table-fn"}^                    0.004
  4     Reed \[[@b63-kjim-2017-098]\]            2005   SAB           16.6 ± 12.7^[d](#tfn7-kjim-2017-098){ref-type="table-fn"}^          9.3 ± 8.5^[d](#tfn7-kjim-2017-098){ref-type="table-fn"}^            \< 0.0001
  5     Cordova \[[@b66-kjim-2017-098]\]         2004   SAB           16 (6--25, 1--211)^[e](#tfn8-kjim-2017-098){ref-type="table-fn"}^   14 (7--30, 1--273)^[e](#tfn8-kjim-2017-098){ref-type="table-fn"}^   NR
  6     Osmon \[[@b67-kjim-2017-098]\]           2004   SAB           22.1 ± 24.9^[d](#tfn7-kjim-2017-098){ref-type="table-fn"}^          13.2 ± 13.5^[d](#tfn7-kjim-2017-098){ref-type="table-fn"}^          0.001
  7     Tumbarello \[[@b75-kjim-2017-098]\]      2002   SAB           49 ± 27^[d](#tfn7-kjim-2017-098){ref-type="table-fn"}^              24 ± 16^[d](#tfn7-kjim-2017-098){ref-type="table-fn"}^              \< 0.001
  8     Soriano \[[@b82-kjim-2017-098]\]         2000   SAB           18^[f](#tfn9-kjim-2017-098){ref-type="table-fn"}^                   8^[f](#tfn9-kjim-2017-098){ref-type="table-fn"}^                    \< 0.00001

LOS, length of hospital stay; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-susceptible *S. aureus*; SAB, *S. aureus* bacteremia; NR, not recorded.

Mean (range).

Mean (95% confidence interval).

Median.

Mean ± SD.

Median (interquartile range, range),

Mean.

###### 

Medical costs

  No                                                                                          Author                                                                                      Year                    Medical costs                                                                            *p* value                                                                               
  ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ----------------------
  1                                                                                           Rubio-Terres \[[@b37-kjim-2017-098]\]                                                       2009                    €11,044.59/episode^[a](#tfn10-kjim-2017-098){ref-type="table-fn"}^                       €9839.25/episode^[a](#tfn10-kjim-2017-098){ref-type="table-fn"}^                        \-
  2                                                                                           Ben-David \[[@b33-kjim-2017-098]\]                                                          2009                    ICU origin: \$113,852 (48,961--55,001)^[b](#tfn11-kjim-2017-098){ref-type="table-fn"}^   ICU origin: \$42,137 (32,388--74,781)^[b](#tfn11-kjim-2017-098){ref-type="table-fn"}^   ICU origin: \< 0.001
  General origin: \$53,409 (32,945--84,053)^[b](#tfn11-kjim-2017-098){ref-type="table-fn"}^   General origin: \$35,131 (18,340--50,896)^[b](#tfn11-kjim-2017-098){ref-type="table-fn"}^   General origin: 0.005                                                                                                                                                                                    
  3                                                                                           Greiner \[[@b46-kjim-2017-098]\]                                                            2006                    €24,931^[a](#tfn10-kjim-2017-098){ref-type="table-fn"}^                                  €10,573^[a](#tfn10-kjim-2017-098){ref-type="table-fn"}^                                 \< 0.05
  4                                                                                           Lodise \[[@b62-kjim-2017-098]\]                                                             2005                    \$21,577 (17,061--27,290)^[c](#tfn12-kjim-2017-098){ref-type="table-fn"}^                \$11,668 (9,550--14,223)^[c](#tfn12-kjim-2017-098){ref-type="table-fn"}^                0.001
  5                                                                                           Reed \[[@b63-kjim-2017-098]\]                                                               2005                    \$28,297 ± 23,619^[d](#tfn13-kjim-2017-098){ref-type="table-fn"}^                        \$16,066 ± 16,337^[d](#tfn13-kjim-2017-098){ref-type="table-fn"}^                       \< 0.0001
  6                                                                                           Cosgrove \[[@b76-kjim-2017-098]\]                                                           2001                    \$26,424 (14,006--50,484)^[b](#tfn11-kjim-2017-098){ref-type="table-fn"}^                \$19,212 (9,999--36,548)^[b](#tfn11-kjim-2017-098){ref-type="table-fn"}^                0.008

MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-susceptible *S. aureus*; ICU, intensive care unit.

Mean.

Median (interquartile range).

Mean (95% confidence interval).

Mean ± SD.

[^1]: These authors contributed equally to this work.
